JP2013517307A - 心臓病の処置 - Google Patents

心臓病の処置 Download PDF

Info

Publication number
JP2013517307A
JP2013517307A JP2012549249A JP2012549249A JP2013517307A JP 2013517307 A JP2013517307 A JP 2013517307A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2012549249 A JP2012549249 A JP 2012549249A JP 2013517307 A JP2013517307 A JP 2013517307A
Authority
JP
Japan
Prior art keywords
ser
lys
arg
glu
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012549249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517307A5 (enExample
Inventor
セベルウ ペテルセン イェルゲン
ルイーズ キョエルビー アンネ
スコウガード マリー
デュールンド ペデルセン ヘンリック
アクセルセン レネ
リベル ディッテ
マイアー エディ
シュルツ ハンセン リー
フォスゲラウ ケルド
デュー ラーセン ビャルネ
Original Assignee
ジーランド ファーマ アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013517307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジーランド ファーマ アクティーゼルスカブ filed Critical ジーランド ファーマ アクティーゼルスカブ
Publication of JP2013517307A publication Critical patent/JP2013517307A/ja
Publication of JP2013517307A5 publication Critical patent/JP2013517307A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2012549249A 2010-01-20 2011-01-20 心臓病の処置 Withdrawn JP2013517307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
US61/296,657 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074097A Division JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Publications (2)

Publication Number Publication Date
JP2013517307A true JP2013517307A (ja) 2013-05-16
JP2013517307A5 JP2013517307A5 (enExample) 2014-03-13

Family

ID=43928934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012549249A Withdrawn JP2013517307A (ja) 2010-01-20 2011-01-20 心臓病の処置
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074097A Active JP6200025B2 (ja) 2010-01-20 2016-04-01 心臓病の処置

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503474A (ja) * 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
JP2019112437A (ja) * 2013-10-17 2019-07-11 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2021506955A (ja) * 2017-12-21 2021-02-22 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) * 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
KR20140114845A (ko) * 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
WO2014096179A1 (en) * 2012-12-19 2014-06-26 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
CR20170293A (es) * 2014-12-30 2017-11-03 Hanmi Pharm Ind Co Ltd Derivados de glucagón con estabilidad mejorada
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
SG11201811697SA (en) 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
SG10201911851VA (en) 2016-12-09 2020-02-27 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
CN115304666B (zh) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
FI3735295T3 (fi) 2018-01-03 2024-11-20 Mederis Diabetes Llc Parannetut peptidilääkkeet nashin ja muiden sairauksien hoitoon
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509078A (ja) * 1998-02-13 2002-03-26 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
JP2004512311A (ja) * 2000-10-20 2004-04-22 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
WO2008101017A2 (en) * 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509078A (ja) * 1998-02-13 2002-03-26 アミリン・ファーマシューティカルズ，インコーポレイテッド エキセンジンおよびｇｌｐ−１の変力および利尿効果
JP2004512311A (ja) * 2000-10-20 2004-04-22 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療
WO2008101017A2 (en) * 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
WO2009155258A2 (en) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6015002015; Ｃｉｒｃｕｌａｔｉｏｎ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．ＸＸＶＩ, 1970, ｐ．２２５-２３３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019112437A (ja) * 2013-10-17 2019-07-11 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2017503474A (ja) * 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
JP2021506955A (ja) * 2017-12-21 2021-02-22 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2022033724A (ja) * 2017-12-21 2022-03-02 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP7658877B2 (ja) 2017-12-21 2025-04-08 イーライ リリー アンド カンパニー インクレチン類似体およびその使用
JP2023525260A (ja) * 2020-05-09 2023-06-15 天津薬物研究院有限公司 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途

Also Published As

Publication number Publication date
MX2012008440A (es) 2012-08-15
PH12012501494A1 (en) 2012-10-22
IL220876A0 (en) 2012-09-24
AU2011206979B2 (en) 2015-09-10
US20130157953A1 (en) 2013-06-20
JP2016138127A (ja) 2016-08-04
CN102892425A (zh) 2013-01-23
AU2011206979A1 (en) 2012-08-02
WO2011088837A1 (en) 2011-07-28
EP2525809A1 (en) 2012-11-28
BR112012018104A2 (pt) 2017-10-17
CL2012002037A1 (es) 2012-09-07
EA201290540A1 (ru) 2013-03-29
NZ601167A (en) 2014-12-24
JP6200025B2 (ja) 2017-09-20
KR20120128129A (ko) 2012-11-26
EP2525809B1 (en) 2016-08-03
CA2786934A1 (en) 2011-07-28
MX342409B (es) 2016-09-28
EA026384B1 (ru) 2017-04-28

Similar Documents

Publication Publication Date Title
JP6200025B2 (ja) 心臓病の処置
JP6849720B2 (ja) グルカゴン類似体
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
CN105745222B (zh) 酰化胰高血糖素类似物
JP6334537B2 (ja) グルカゴン類似体
JP5635530B2 (ja) グルカゴン類似体
JP5635529B2 (ja) グルカゴン類似体
US10766939B2 (en) Amylin analogues
US20110293587A1 (en) Glucagon analogues
TW201202265A (en) Glucagon analogues
KR20140114845A (ko) 글루카곤 유사체
CN103068841A (zh) 胰高血糖素类似物
JP2012532898A (ja) アシル化グルカゴン類似体
CN107636010A (zh) 酰化胰高血糖素类似物
JP6006264B2 (ja) グルカゴン類似体
JP5912150B2 (ja) グルカゴン類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160427

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160519